Profile data is unavailable for this security.
About the company
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-39.70m
- Incorporated2019
- Employees29.00
- LocationElevation Oncology Inc101 Federal Street, Suite 1900BOSTON 02110United StatesUSA
- Phone+1 (716) 371-1125
- Fax+1 (302) 697-4597
- Websitehttps://elevationoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chemomab Therapeutics Ltd - ADR | 0.00 | -15.00m | 31.65m | 20.00 | -- | 2.46 | -- | -- | -7.69 | -7.69 | 0.00 | 0.6954 | 0.00 | -- | -- | 0.00 | -69.12 | -- | -92.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
Lumos Pharma Inc | 1.49m | -35.75m | 31.93m | 33.00 | -- | 3.11 | -- | 21.49 | -4.43 | -4.43 | 0.1841 | 1.26 | 0.0382 | -- | 7.41 | 45,030.30 | -91.98 | -29.78 | -107.92 | -32.32 | -- | -- | -2,405.72 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
Ocean Biomedical Inc | 0.00 | -98.59m | 32.22m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
Clene Inc. | 442.00k | -30.46m | 32.35m | 82.00 | -- | -- | -- | 73.19 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 32.65m | 4.00 | -- | 9.38 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Tempest Therapeutics Inc | 0.00 | -31.75m | 34.03m | 17.00 | -- | 1.95 | -- | -- | -1.64 | -1.64 | 0.00 | 0.6921 | 0.00 | -- | -- | 0.00 | -87.09 | -57.10 | -127.72 | -71.20 | -- | -- | -- | -- | -- | -368.16 | 0.3861 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Xilio Therapeutics Inc | 2.36m | -65.53m | 34.24m | 73.00 | -- | 1.02 | -- | 14.53 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 34.58m | 163.00 | -- | 0.1695 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Elevation Oncology Inc | 0.00 | -39.70m | 34.63m | 29.00 | -- | 0.3957 | -- | -- | -0.8399 | -0.8399 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -35.30 | -- | -37.14 | -- | -- | -- | -- | -- | -- | -25.25 | 0.2765 | -- | -- | -- | 51.93 | -- | -- | -- |
Curis Inc | 10.16m | -47.57m | 35.34m | 48.00 | -- | -- | -- | 3.48 | -8.24 | -8.24 | 1.76 | -0.1175 | 0.1509 | -- | 4.12 | 211,687.50 | -70.62 | -37.25 | -90.04 | -41.12 | 98.30 | 96.05 | -468.18 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Gain Therapeutics Inc | 0.00 | -21.60m | 36.52m | 29.00 | -- | 3.05 | -- | -- | -1.33 | -1.33 | 0.00 | 0.4682 | 0.00 | -- | -- | 0.00 | -115.33 | -- | -170.44 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0396 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
Estrella Immunopharma Inc | 0.00 | -2.16m | 36.74m | -- | -- | 3.53 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
Dyadic International Inc | 1.80m | -7.74m | 36.85m | 7.00 | -- | 11.63 | -- | 20.42 | -0.2675 | -0.2675 | 0.0624 | 0.1075 | 0.1662 | -- | 3.55 | 257,731.40 | -71.33 | -36.82 | -87.19 | -39.85 | 50.01 | 22.47 | -429.07 | -410.16 | -- | -- | 0.6324 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
Quince Therapeutics Inc | 0.00 | -53.12m | 37.45m | 32.00 | -- | 0.7973 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 37.79m | 4.00 | -- | -- | -- | 55.26 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Great Point Partners LLCas of 06 Aug 2024 | 3.88m | 6.56% |
Logos Global Management LPas of 30 Jun 2024 | 3.85m | 6.51% |
Farallon Capital Management LLCas of 30 Jun 2024 | 3.60m | 6.09% |
Tang Capital Management LLCas of 30 Jun 2024 | 3.06m | 5.18% |
Empery Asset Management LPas of 31 Dec 2023 | 2.84m | 4.81% |
Aisling Capital Management LPas of 30 Jun 2024 | 2.83m | 4.80% |
Balyasny Asset Management LPas of 30 Jun 2024 | 2.48m | 4.20% |
Braidwell LPas of 30 Jun 2024 | 2.48m | 4.19% |
Hudson Bay Capital Management LPas of 30 Jun 2024 | 2.40m | 4.06% |
BVF Partners LPas of 30 Jun 2024 | 2.31m | 3.91% |